Vibiosophen

Vibiosphen is a biotechnology contract research organization (CRO) founded in 2014 and based in Labège, France. The company specializes in the field of infectious diseases, leveraging microbiology to develop preclinical solutions for human, animal, and dermocosmetic health. Their core capabilities include the design and execution of in vitro and in vivo efficacy testing, safety assessments, and pharmacokinetic and pharmacodynamic studies. The company utilizes a broad catalogue of predictive pharmacological models, including standard and custom-made mouse experimental models and organoids, to assist in the development of new therapies such as antibiotics, peptides, biologics, and bacteriophages.

By focusing on the critical challenge of antimicrobial resistance and the development of anti-infective therapies, Vibiosphen supports healthcare and biotechnology partners in navigating the drug development pipeline. The company’s integrated approach enables the validation of innovative molecules for treating various infections, including pneumonia, septicemia, urinary tract, gastrointestinal, and skin infections. Their services are designed to help researchers and pharmaceutical companies optimize preclinical validation, reduce the time to market for novel therapeutics, and discover new strategies to address the global need for safer and more effective health solutions.